Effective testing at the point of care
The BD Veritor™ Plus System offers what your organization needs to conduct antigen testing for respiratory infections and can help you successfully implement a reliable diagnostic testing program.
BD Veritor™ Plus System
SARS-CoV-2 & Influenza A+B rapid antigen testing
One sample. Three tests. Reliable results. Combo testing for COVID-19** and Flu A+B is here.
Even as clinical teams face the constantly evolving changes of COVID-19, they are also addressing flu season across many parts of the world. BD, working with clinicians and diagnostic experts, has developed a new assay that allows you to provide reliable, rapid point-of-care testing and results for SARS-CoV-2 and Influenza A and B from the same patient sample.
Why test for both?
The BD Veritor™ System combined assay allows you to get the answer you need for fast decision-making. It gives you results for all three infections with a single sample collection from the patient. Most importantly, it gives you a simple, reliable tool to efficiently help you put patients on the right care path.
Available Summer 2021
**The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for the qualitative detection of SARS-CoV-2 and/or influenza A and B nucleocapsid antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the first six days of symptom onset
•This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
•This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens.
•This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.